Long-term follow-up for patients treated with CS-101

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the long-term safety and efficacy of CS-101 in participants who previously received this treatment in an earlier study. Participants will be monitored for up to two years following their last follow-up visit after the CS-101 infusion. The aim is to gather comprehensive data on the effects and outcomes of the treatment over an extended period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
* Participants must have received CS-101 infusion in last IIT study

Exclusion Criteria:

* There are no exclusion criteria

Where it's running

• Children's Hospital of Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Xiaowen Zhai, M.D. — Children's Hospital of Fudan University
• Study coordinator: Xiaowen Zhai, M.D.
• Email: zhaixiaowendy@163.com
• Phone: +86-021-64931126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Thalidomide with Danazol and Prednisolone for difficult beta-thalassemia in children

  This trial tests whether adding danazol and prednisolone to thalidomide helps children with transfusion-dependent beta-thalassemia who did not respond to thalidomide alone.

  Recruiting Phase 3 Khyber Medical University Peshawar · Peshawar, Khyber Pakhtunkhwa · NCT07884773

• Partial stem cell transplant for sickle cell disease and beta-thalassemia using matched donors

  This study tests a partial stem cell transplant from matched donors to help people with severe sickle cell disease or beta-thalassemia see if more donor cells can persist long-term.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07599176

• Testing 9MW3011 for patients with non-transfusion-dependent beta-thalassemia

  This study is testing a new drug called 9MW3011 to see if it is safe and effective for people with non-transfusion-dependent beta-thalassemia.

  Recruiting at 2 sites Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Nanning, Guangxi and 1 other locations · NCT06772766

• Gene editing of your own blood stem cells to boost fetal hemoglobin for severe sickle cell disease and beta-thalassemia

  This trial will test whether editing a specific gene in patients' own blood stem cells can raise fetal hemoglobin and reduce symptoms in people aged 13–40 with severe sickle cell disease or transfusion-dependent beta-thalassemia.

  Recruiting Phase 1 Boston Children's Hospital · Boston, Massachusetts · NCT06647979

• Observational study on patients with Beta-Thalassemia treated with betibeglogene autotemcel

  This study is looking at how well betibeglogene autotemcel works and its long-term safety for people with beta-thalassemia who have already received this treatment.

  Recruiting at 6 sites Genetix Biotherapeutics Inc. · Oakland, California and 5 other locations · NCT06271512

• Assessing the safety of luspatercept in Korean patients with myelodysplastic syndrome or beta thalassemia

  This study is testing how safe the drug luspatercept is for adult Korean patients with myelodysplastic syndrome or beta thalassemia while they are being treated.

  Recruiting Bristol-Myers Squibb · Seoul and 1 other locations · NCT06073860

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.